Dx Deals: New Deal Expands Reach of Oral Cancer Test to Dental Practices
Recently announced collaboration between Viome and Henry Schein allows dentists to offer sample collection for Viome’s assay to patients
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Recently announced collaboration between Viome and Henry Schein allows dentists to offer sample collection for Viome’s assay to patients
So far, it appears many post-PHE COVID-19 tests will be panels for detecting and differentiating among multiple respiratory viruses.
A recent report offers new insight into bankruptcy trends within the sector starting before the COVID-19 pandemic.
In terms of Medicare coverage, 2023 is shaping up to be a fruitful year—here are five of the most significant approvals so far.
Increasing medical and consumer debt is likely to get worse, meaning billing and collections may get even tougher for labs.
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
The wave of layoffs, which began last year with the declines in COVID-19 testing sales, has gathered momentum in 2023.
The bill is designed to provide Medicare patients faster access to innovative technology approved by the FDA.
April was among the busiest months, in recent memory, in terms of both deal volume and significance in the diagnostics industry.
No company better embodies the vicissitudes of running a COVID-19-focused diagnostics business during the pandemic period than Lucira Health.
HHS secretary takes action to ensure that EUAs remain in effect until the “significant potential” for a COVID-19 PHE no longer exists.